Safety Study of ABT-263 in Combination With Gemzar (Gemcitabine) in Subjects With Solid Tumors



Status:Archived
Conditions:Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:September 2009
End Date:November 2011

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

A Phase 1 Safety and Pharmacokinetic Study of ABT-263 in Combination With Gemzar (Gemcitabine) in Subjects With Solid Tumors


This is a Phase 1 open-label study evaluating the safety of navitoclax (ABT-263) when
combined with a standard regimen of gemcitabine in approximately 25 subjects with solid
tumors and measurable disease.



We found this trial at
3
sites
Brigham & Women's Hospital Women's Health Center
850 Boylston Street
Chestnut Hill, Massachusetts 02467
1-800-BWH-9999
Brigham & Women's Hospital Women's Health Center At Brigham and Women
?
mi
from
Chestnut Hill, MA
Click here to add this to my saved trials
Clinical Trial Facility in Durham North Carolina
Durham, North Carolina 27710
?
mi
from
Durham, NC
Click here to add this to my saved trials
Clinical Trial Facility in Miami Florida
Miami, Florida 33136
?
mi
from
Miami, FL
Click here to add this to my saved trials